employed PD1-antiMUC16 dual-target CAR-T cells to treat epithelial ovarian cancer, demonstrating in vivo that these dual-target CAR-T cells exhibited greater killing efficacy compared to their single-target counterparts and significantly prolonged survival in a mouse model, underscoring MUC16’s central role in immunotherapy (87). The gene discussed is MUC16; the disease is ovarian carcinoma.